Analysis of Drug Development Paradigms for Immune Checkpoint inhibitors.

about

Analysis of Drug Development Paradigms for Immune Checkpoint inhibitors.

Item

http://www.wikidata.org/entity/Q47355563

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Analysis of Drug Development Paradigms for Immune Checkpoint inhibitors.

@en

Analysis of Drug Development Paradigms for Immune Checkpoint inhibitors.

@nl

type

Item

label

Analysis of Drug Development Paradigms for Immune Checkpoint inhibitors.

@en

Analysis of Drug Development Paradigms for Immune Checkpoint inhibitors.

@nl

prefLabel

Analysis of Drug Development Paradigms for Immune Checkpoint inhibitors.

@en

Analysis of Drug Development Paradigms for Immune Checkpoint inhibitors.

@nl

P1476

Analysis of Drug Development Paradigms for Immune Checkpoint inhibitors.

@en

P2093

Debora de Melo Gagliato

http://www.w3.org/2001/XMLSchema#string

Denis L Jardim

http://www.w3.org/2001/XMLSchema#string

Francis J Giles

http://www.w3.org/2001/XMLSchema#string

P2860

The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses

Immune Checkpoint Blockade in Cancer Therapy

Nivolumab plus ipilimumab in advanced melanoma.

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer.

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.

FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma.

Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials.

P31

scholarly article

review article

meta-analysis

P356

10.1158/1078-0432.CCR-17-1970

http://www.w3.org/2001/XMLSchema#string

P407

English

P50

Razelle Kurzrock

P577

2017-12-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29212781

http://www.w3.org/2001/XMLSchema#string

P932

5899646

http://www.w3.org/2001/XMLSchema#string